

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rules 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Resolutions of the Fifth Meeting of the Fourth Session of the Board of Directors”, “Shanghai Junshi Biosciences Co., Ltd.* Announcement on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms” and “Shanghai Junshi Biosciences Co., Ltd.* Announcement Regarding the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share Incentive Scheme” published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 November 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive directors; Mr. Tang Yi as non-executive director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming and Dr. Yang Yue as independent non-executive directors.

* *For identification purpose only*

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on the Resolutions of the Fifth Meeting
of the Fourth Session of the Board of Directors

The Board of Directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

1. The Convening of The Meeting

The fifth meeting of the fourth session of the Board of Directors of Shanghai Junshi Biosciences Co., Ltd.* (the “Company”) was convened on November 29, 2024 by way of on-site and correspondence voting. The meeting was presided over by Mr. Xiong Jun, the chairman of the Board. 13 directors were expected to attend the meeting and 13 directors attended the meeting. The convening and holding procedures of the meeting were in compliance with the Company Law of the People’s Republic of China and the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*. According to relevant regulations, the resolutions of the meeting are legal and valid.

2. The Deliberations of The Meeting

(1) The Proposal on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms was considered and approved

Voting results: 13 votes in favour, 0 vote against and 0 abstention.

For details, please refer to the announcement of the Company published on the website of Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(2) The Proposal on Change of Registered Address of the Company, Amendments of the Articles of Association and the Industrial and Commercial Registration of the Changes was considered and approved

Voting results: 13 votes in favour, 0 vote against and 0 abstention.

This proposal shall be submitted to the general meeting of the Company for consideration.

For details, please refer to the announcement of the Company published on the website of Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(3) The Proposal on the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share Incentive Scheme was considered and approved

Voting results: 13 votes in favour, 0 vote against and 0 abstention.

For details, please refer to the announcement of the Company published on the website of Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(4) The Proposal on Nomination of Candidates for Independent Non-Executive Director was considered and approved

This proposal has been approved by the Nomination Committee, and it was agreed to be submitted to the Board of Directors for consideration.

Voting results: 13 votes in favour, 0 vote against and 0 abstention.

This proposal shall be submitted to the general meeting of the Company for consideration.

For details, please refer to the announcement of the Company published on the website of Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(5) The Proposal on Holding the First Extraordinary General Meeting in 2024 was considered and approved

Voting results: 13 votes in favour, 0 vote against and 0 abstention.

For details, please refer to the announcement of the Company published on the website of Shanghai Stock Exchange (www.sse.com.cn) on the same date.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

30 November 2024

Shanghai Junshi Biosciences Co., Ltd.*

Announcement on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms

The Board of Directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading statement or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important notice:

- Shanghai Junshi Biosciences Co., Ltd.* (hereinafter referred to as the “Company”), promises that under the condition of not affecting the normal progress of the Company’s investment plans funded with the proceeds raised, the Company proposes to deposit part of temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits.
- As of 30 June 2024, proceeds from the initial public offering of A shares (“IPO proceeds”) had all been used according to committed investment projects (excluding surplus proceeds). It has been intended for the proceeds from the issuance of A shares to target subscribers in 2022 (“refinancing proceeds”) to be invested in the research and development projects of innovative drugs and the Junshi Biotech Scientific Headquarters and R&D Base Project, which are progressing normally. The proceeds raised by the Company will be used in a reasonable and timely manner according to the overall progress of the investment projects. Depositing temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits will not affect the construction of the investment projects.

I. Overview of the Proceeds

In accordance with the “Approval Regarding the Registration of Shares Issued by Shanghai Junshi Biosciences Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2022] No. 2616)” (《關於同意上海君實生物醫藥科技股份有限公司向特定對象發行股票註冊的批復》(證監許可〔2022〕2616號)) issued by the China Securities

Regulatory Commission, the Company was approved to issue 70,000,000 RMB-denominated ordinary shares to target subscribers at an issue price of RMB53.95 per share, with the total proceeds amounting to RMB3,776,500,000. Net proceeds after deducting issuance expenses (excluding tax) amounted to RMB3,744,802,800. The above funds have become fully available on 23 November 2022. RSM China (容誠會計師事務所 (特殊普通合伙)) has verified the availability of the proceeds from the issuance of shares to target subscribers and issued the “Capital Verification Report” (Rong Cheng Yan Zi [2022] No. 230Z0337 (容誠驗字[2022] 230Z0337號《驗資報告》) on 24 November 2022.

In order to regulate the management and use of proceeds of the Company and to safeguard the interests of investors, the Company established a special account for such proceeds. Upon receipt, all proceeds were deposited into the special account established by the Company, and a Tripartite Agreement on Supervision of Special Deposit Account for Proceeds*(《募集資金專戶存儲三方監管協議》) was entered into by the Company, the sponsor institution, and the commercial bank in which the proceeds were deposited. The Company has also signed the Quadripartite Agreement on Supervision of Special Deposit Accounts for Proceeds*(《募集資金專戶存儲四方監管協議》) with the subsidiaries implementing the investment projects, the sponsor institution and the commercial bank where the proceeds are deposited.

II. Information Relevant to the Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms

(I) Purpose

The purpose of the deposits is to improve the efficiency of the use of the proceeds, to make reasonable use of part of the temporarily idle proceeds, and to increase the capital return for the Company and obtain more returns for the Company and its shareholders under the condition that the construction and use of the investment projects funded by the proceeds will not be affected, the safety of the proceeds can be ensured and there will be no disguised change in the use of the proceeds.

(II) Types of Products

In accordance with the relevant regulations, the Company will strictly control risks and propose to deposit part of temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits, and such products shall not be used for pledge or investment for the purpose of securities investment.

(III) Validity Period of the Resolution

It shall be valid for 12 months from the date of consideration and approval by the board of directors of the Company.

(IV) Funding sources, Investment Amount and Term

The Company proposes to deposit part of the temporary idle proceeds not exceeding RMB2.8 billion (inclusive) in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits. Based on the use of the proceeds and the Company's operating conditions, the temporarily idle proceeds will be invested in the aforesaid products in several tranches for different terms, with the maximum period not exceeding 12 months. Within the aforesaid amount and term, the Company could use the temporarily idle proceeds on a revolving basis.

(V) Implementation Method

Within the aforesaid amount and term, the board of directors of the Company delegates to the chairman of the Board of Directors of the Company the authority to make investment decisions and sign relevant legal documents. The finance department of the Company shall be responsible for the organization and implementation of specific matters.

(VI) Information Disclosure

The Company will comply with its information disclosure obligations in a timely manner in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange; and will not change the use of the proceeds in a disguised manner.

(VII) Allocation of Income

The Company's income from deposit of temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits will be prioritized to make up for the shortfall in the investment amount of investment projects funded by the proceeds and the working capital required for the Company's daily operation. The Company will manage and use the proceeds in strict compliance with the requirements of regulatory measures of the China Securities Regulatory Commission and the Shanghai Stock Exchange on the proceeds, and will return the funds back to the special account for proceeds upon the expiration of the call deposits, portfolio deposits, certificates of deposit and structured deposits.

III. Impact on Daily Operation of the Company

The proposed deposit of temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits by the Company is implemented on the premise of ensuring the funds required for the Company's investment projects funded by the proceeds and the safety of the proceeds, which will neither affect its normal turnover of daily funds and normal progress of the investment projects funded by the proceeds, nor the normal development of the Company's main business.

As of 30 June 2024, the IPO proceeds had all been used according to committed investment projects (excluding surplus proceeds). It has been intended for the refinancing proceeds to be invested in the research and development projects of innovative drugs and the Junshi Biotech Scientific Headquarters and R&D Base Project, which are progressing normally. The proceeds raised by the Company will be used in a reasonable and timely manner according to the overall progress of the investment projects, and depositing the temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposits and structured deposits will not affect the construction of the investment projects.

Meanwhile, the timely deposit of temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits enables the achievement of a certain amount of investment income, which is conducive to further improving the overall performance of the Company and seeking better return on investment for the Company and its shareholders.

IV. Investment Risk and Risk Control Measures

(I) Investment Risks

Although the Company intends to select call deposits, portfolio deposits, certificates of deposit and structured deposits products which are low-risk investment products, the financial market is highly susceptible to the macro-economy. Therefore, the Company will intervene to such extent as and when appropriate, taking account of the economic situation and changes in financial market. However, the possibility that such investment may be affected by market fluctuation cannot be ruled out.

(II) Risk Control Measures

1. The board of directors of the Company authorizes the chairman of the Board of Directors to exercise the decision-making rights and execute relevant contractual documents in relation to the investment, including but not limited to selecting high-

quality cooperative banks, specifying the amount and term, choosing the categories of products, and executing contracts and agreements. The financial department of the Company is responsible for the organization and implementation of specific matters, and will analyze and monitor the investment of the bank's related products and project progress in a timely manner. Once adverse factors are identified or judged, corresponding preservation measures will be taken in time to control investment risks.

2. The internal audit department of the Company is responsible for reviewing the approval, actual operation, capital utilization and the profits and losses in relation to the purchase of call deposits, portfolio deposits, certificates of deposit and structured deposits, urging the finance department to deal with relevant accounts in a timely manner and conducting verification on the accounting treatment. It shall conduct a comprehensive inspection on all the call deposits, portfolio deposits, certificates of deposit and structured deposits of banks at the end of each quarter and reports to the audit committee on the reasonable expectation of potential gains and losses of each investment on a prudent basis.

3. The independent non-executive directors and the Board of Supervisors shall supervise and inspect the capital utilization and may engage professional institutions for audit when necessary.

4. The Company must conduct the relevant business in strict compliance with the relevant regulations, such as the “Regulatory Guidance for Listed Companies No.2 - Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies” (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the “Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation” (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) and the Management Policies for Proceeds Raised of the Company.

V. Review Procedures

On 29 November 2024, the “Proposal on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms” (《關於將暫時閑置募集資金以通知存款等方式存放的議案》) was considered and approved at the fifth meeting of the fourth session of the board of directors and the fourth meeting of the fourth session of the board of supervisors of the Company, under which consent was given to deposit part of temporarily idle proceeds not exceeding RMB2.8 billion (inclusive) in the forms of

call deposits, portfolio deposits, certificates of deposit and structured deposits, provided that it does not affect the normal progress of the Company's investment plans funded with the proceeds raised, which is valid for 12 months from the date of consideration and approval by the board of directors. Within the aforesaid amount and term, the Company could use the proceeds on a revolving basis. Pursuant to the relevant regulations including the "Regulatory Guidance for Listed Companies No.2 - Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies" (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the "Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation" (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》), the "Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*" (《上海君實生物醫藥科技股份有限公司章程》) and the "Management Policies for Proceeds Raised of Shanghai Junshi Biosciences Co., Ltd.*" (《上海君實生物醫藥科技股份有限公司募集資金管理制度》), such matter is not subject to the consideration at the general meeting.

VI. Special Opinions

(I) Opinions of the Board of Supervisors

The board of supervisors of the Company is of the opinion that provided that the Company's investment plans funded with proceeds raised progress normally, the Company's deposit of part of temporarily idle proceeds not exceeding RMB2.8 billion (inclusive) in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits is conducive to improving the efficiency of and gains from the use of proceeds, and is in the interest of the Company and its shareholders as a whole. The related contents and procedures are in compliance with the laws, regulations and regulatory documents including the "Regulatory Guidance for Listed Companies No.2 - Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies" (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the "Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation" (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) as well as the requirements under the "Management Policies for Proceeds Raised of Shanghai

Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司募集資金管理制度》)。The Company’s present deposit of part of the temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits does not conflict with the implementation plan of investment projects funded with proceeds raised and will not affect the normal progress of the investment projects funded with proceeds raised, and there is no circumstance where it will change the target use of proceeds in effect or become detrimental to the interests of the shareholders of the Company.

Therefore, the board of supervisors of the Company agree to the deposits of part of temporarily idle proceeds not exceeding RMB2.8 billion (inclusive) in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits.

(II) Verification opinion of the Sponsor Institution

Upon verification, Haitong Securities Co., Ltd., the sponsor institution of the Company, is of the view that:

Temporarily idle proceeds to be partly deposited as call deposits, portfolio deposits, certificates of deposit and structured deposits has been considered and approved by the Board of Directors and Board of Supervisors of the Company, which is in compliance with the necessary approval procedures. By depositing part of the temporarily idle proceeds in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits, the Company can improve the fund utilization, which will not involve any disguised change in the use of proceeds, will not affect the normal progress of the investment plans for the proceeds, and is in compliance with relevant requirements including the “Regulatory Guidance for Listed Companies No. 2 – Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies” (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the “Rules Governing the Listing of Securities on the STAR Market of the Shanghai Stock Exchange” (《上海證券交易所科創板股票上市規則》) and the “Guideline No. 1 for the Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation” (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) as well as the requirements under the management policy on proceeds of the Company. The sponsor institution has no objection to the deposit of part of temporarily idle proceeds in the forms of call

deposits, portfolio deposits, certificates of deposit and structured deposits.

VII. Attachments to the Online Announcement

“Verification Opinion of Haitong Securities Co., Ltd. on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms by Shanghai Junshi Biosciences Co., Ltd.*” issued by the sponsor institution, Haitong Securities Co., Ltd. (《海通證券股份有限公司關於上海君實生物醫藥科技股份有限公司將暫時閒置募集資金以通知存款等方式存放的核查意見》).

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

30 November 2024

Shanghai Junshi Biosciences Co., Ltd.*
Announcement Regarding the Nullification of Certain
Restricted Shares Granted but yet to be Attributed
under the 2020 Restricted Share Incentive Scheme

The Board of Directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading statement or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important Notice:

The “Proposal on the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share Incentive Scheme” (《關於作廢處理2020年限制性股票激勵計劃部分已授予但尚未歸屬限制性股票的議案》) has been considered and approved at the fifth meeting of the fourth session of the Board of Directors and the fourth meeting of the fourth session of the Board of Supervisors convened by Shanghai Junshi Biosciences Co., Ltd.* (the “Company”) on 29 November 2024. Pursuant to the requirements of the Company’s 2020 Restricted Share Incentive Scheme (the “Incentive Scheme”), the restricted shares granted but yet to be attributed under the 2020 Restricted Share Incentive Scheme will be nullified. The details of related matters are hereby announced as follows:

I. Decision-making procedures and information disclosure of the Restricted Share Incentive Scheme that have been conducted

(I) On 29 September 2020, the Company convened the twenty-seventh meeting of the second session of the board of directors and the twenty-second meeting of the second session of the board of supervisors, at which the “Proposal on the 2020

Restricted Share Incentive Scheme (Draft) and its Summary” (《關於<公司 2020 年限制性股票激勵計劃(草案)>及其摘要的議案》) and other relevant proposals were considered and approved. The independent non-executive directors of the Company have expressed their concurring independent opinion on such matter. The board of supervisors of the Company verified relevant matters of the Incentive Scheme and issued relevant verification opinion. On 30 September 2020, the Company published relevant announcements on the website of the Shanghai Stock Exchange (www.sse.com.cn).

(II) On 30 September 2020, the Company published the “Announcement on Public Solicitation of Voting Rights by Proxy Form by Independent Non-Executive Directors of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司關於獨立非執行董事公開徵集委託投票權的公告》)(Announcement No.: Lin 2020-028) on the website of the Shanghai Stock Exchange (www.sse.com.cn). Pursuant to the proxy forms of other independent non-executive directors of the Company, Mr. Zhang Chun, an independent non-executive director and being the soliciting party, solicited voting rights from all A Shareholders of the Company in respect of the relevant resolutions of the Incentive Scheme considered at the 2020 third extraordinary general meeting and the 2020 second class meeting of A Shareholders of the Company.

(III) From 30 September 2020 to 9 October 2020, the Company posted an internal notice on the names and positions of the proposed participants for a total of 10 days. Employees of the Company may submit their opinions to the board of supervisors of the Company. As of the end of the notification period, the board of supervisors of the Company had not received any objection from any person regarding the proposed participants. On 15 October 2020, the Company published the “Announcement on the List of Participants under the First Grant of the 2020 Restricted Share Incentive Scheme and Verification Opinion of the Board of Supervisors of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司監事會關於公司 2020 年限制性股票激勵計劃首次授予激勵對象名單的公示情況說明及覈查意見》) (Announcement No.: Lin 2020-031) on the website of the Shanghai Stock Exchange (www.sse.com.cn).

(IV) On 16 November 2020, the Company convened the 2020 third extraordinary general meeting, the 2020 second class meeting of A Shareholders and the 2020 second class meeting of H Shareholders, at which the “Proposal on the Company’s 2020 Restricted Share Incentive Scheme (Draft) and its Summary” (《關於<公司 2020 年限制性股票激勵計劃(草案)>及其摘要的議案》) and other relevant proposals were considered and approved. The implementation of the Incentive Scheme of the Company was approved at the general meetings, and the board of directors was authorized to determine the grant date of the restricted shares, grant restricted shares to eligible participants and conduct all matters necessary for the grant of the restricted shares. On 17 November 2020, the Company published the “Announcement of Resolutions of the 2020 Third Extraordinary General Meeting, the 2020 Second Class Meeting of A Shareholders and the 2020 Second Class Meeting of H Shareholders of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司 2020 年第三次臨時股東大會、2020 年第二次 A 股類別股東大會及 2020 年第二次 H 股類別股東大會決議公告》) (Announcement No.: Lin 2020-036) on the website of Shanghai Stock Exchange (www.sse.com.cn). In the meantime, the Company conducted a self-inspection on the trading of shares of the Company by insiders and participants during the six months prior to the publication of the “2020 Restricted Share Incentive Scheme (Draft) of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司 2020 年限制性股票激勵計劃(草案)》), and no share trading attributable to the use of the inside information was identified. On 17 November 2020, the Company published the “Self- Inspection Report on the Trading of Shares of the Company by Insiders and Participants of the 2020 Restricted Share Incentive Scheme” (《上海君實生物醫藥科技股份有限公司關於 2020 年限制性股票激勵計劃內幕知情人及激勵對象買賣公司股票的自查報告》) (Announcement No.: Lin 2020-037) on the website of Shanghai Stock Exchange (www.sse.com.cn).

(V) On 16 November 2020, the Company convened the twenty-ninth meeting of the second session of the board of directors and the twenty-fourth meeting of the second session of the board of supervisors, at which the “Proposal on the Adjustment of the List of Participants and the Number of Restricted Shares to be Granted for the First

Grant of the 2020 Restricted Share Incentive Scheme” (《關於調整 2020 年限制性股票激勵計劃首次授予激勵對象名單及授予數量的議案》), the “Proposal on the First Grant of Restricted Shares to Participants” (《關於向激勵對象首次授予限制性股票的議案》) and other relevant proposals were considered and approved. The independent non-executive directors of the Company have expressed their concurring independent opinions on such matters. The board of supervisors of the Company has verified and expressed their verification opinions on relevant matters mentioned above. On 17 November 2020, the Company published the “Announcement on the First Grant of Restricted Shares to Participants of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司關於向激勵對象首次授予限制性股票的公告》) (Announcement No.: Lin 2020-042) and the “Announcement on the Adjustment of the List of Participants and the Number of Restricted Shares to be Granted for the First Grant of the 2020 Restricted Share Incentive Scheme of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司關於調整 2020 年限制性股票激勵計劃首次授予激勵對象名單及授予數量的公告》) (Announcement No.: Lin 2020-043) on the website of Shanghai Stock Exchange (www.sse.com.cn).

(VI) On 15 November 2021, the Company convened the fifth meeting of the third session of the board of directors and the fourth meeting of the third session of the board of supervisors, at which the “Proposal on the Grant of Restricted Shares under the Reserved Grant to the Participants” (《關於向激勵對象授予預留部分限制性股票的議案》), the “Proposal on the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share Incentive Scheme” (《關於作廢處理 2020 年限制性股票激勵計劃部分已授予但尚未歸屬限制性股票的議案》) and the “Proposal on the Attribution Condition Fulfilled during the First Attribution Tranche of the First Grant of the Restricted Shares under the 2020 Restricted Share Incentive Scheme of the Company” (《關於公司 2020 年限制性股票激勵計劃首次授予部分第一個歸屬期符合歸屬條件的議案》) were considered and approved. The independent non-executive directors of the Company have expressed their concurring independent opinion on the abovementioned resolutions, and the board of supervisors has verified and expressed their verification opinions on the list of participants of the

reserved grant on the grant date and the list of participants who fulfilled the attribution conditions for the first attribution tranche of the first grant. On 16 November 2021, the Company published the “Announcement on the Grant of Restricted Shares under the Reserved Grant to the Participants of Shanghai Junshi Biosciences Co., Ltd.” (《上海君實生物醫藥科技股份有限公司關於向激勵對象授予預留部分限制性股票的公告》) (Announcement No.: Lin 2021-078), the “Announcement on the Attribution Condition Fulfilled during the First Attribution Tranche of the First Grant of the Restricted Shares under the 2020 Restricted Share Incentive Scheme of Shanghai Junshi Biosciences Co., Ltd.” (《上海君實生物醫藥科技股份有限公司關於 2020 年限制性股票激勵計劃首次授予部分第一個歸屬期符合歸屬條件的公告》) (Announcement No.: Lin 2021-079) and the “Announcement Regarding the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share Incentive Scheme of Shanghai Junshi Biosciences Co., Ltd.” (《上海君實生物醫藥科技股份有限公司關於作廢處理 2020 年限制性股票激勵計劃部分已授予但尚未歸屬限制性股票的公告》) (Announcement No.: Lin 2021-080) on the website of Shanghai Stock Exchange (www.sse.com.cn).

(VII) On 1 November 2022, the Company completed share registration for the first attribution tranche of the first grant of the restricted shares under the Incentive Scheme at Shanghai Branch of the China Securities Depository and Clearing Corporation. On 3 November 2022, the Company published the “Announcement on the Attribution Results during the First Attribution Tranche of the First Grant of the Restricted Shares under the 2020 Restricted Share Incentive Scheme and the Listing of Shares of Shanghai Junshi Biosciences Co., Ltd.” (《上海君實生物醫藥科技股份有限公司關於 2020 年限制性股票激勵計劃首次授予部分第一個歸屬期歸屬結果暨股份上市的公告》) (Announcement No.: Lin 2022-082) on the website of Shanghai Stock Exchange (www.sse.com.cn).

(VIII) On 16 November 2022, the Company convened the fifteenth meeting of the third session of the board of directors and the thirteenth meeting of the third session of the board of supervisors, at which the “Proposal on the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share

Incentive Scheme” (《關於作廢處理 2020 年限制性股票激勵計劃部分已授予但尚未歸屬限制性股票的議案》) and the “Proposal on the Attribution Conditions Fulfilled during the Second Attribution Tranche of the First Grant and the First Attribution Tranche of the Reserved Grant of the Restricted Shares under the 2020 Restricted Share Incentive Scheme of the Company” (《關於公司 2020 年限制性股票激勵計劃首次授予部分第二個歸屬期和預留授予部分第一個歸屬期符合歸屬條件的議案》) were considered and approved. The independent non-executive directors of the Company have expressed their concurring independent opinion on the abovementioned resolutions, and the board of supervisors has verified and expressed their verification opinions on the list of participants who fulfilled the attribution conditions for the second attribution tranche of the first grant and the list of participants who fulfilled the attribution conditions for the first attribution tranche of the reserved grant. On 17 November 2022, the Company published the “Announcement regarding the Second Attribution Tranche of the First Grant and the First Attribution Tranche of the Reserved Grant under the 2020 Restricted Share Incentive Scheme Fulfilling Attribution Conditions of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司關於 2020 年限制性股票激勵計劃首次授予部分第二個歸屬期和預留授予部分第一個歸屬期符合歸屬條件的公告》) (Announcement No.: Lin 2022-088) and the “Announcement Regarding the Nullification of Certain Restricted Shares Granted but yet to be Attributed under the 2020 Restricted Share Incentive Scheme of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司關於作廢處理 2020 年限制性股票激勵計劃部分已授予但尚未歸屬限制性股票的公告》) (Announcement No.: Lin 2022-089) on the website of Shanghai Stock Exchange (www.sse.com.cn).

(IX) On 2 February 2023, the Company completed share registration for the second attribution tranche of the first grant and the first attribution tranche of the reserved grant of the restricted shares under the Incentive Scheme at Shanghai Branch of the China Securities Depository and Clearing Corporation. On 4 February 2023, the Company published the “Announcement Regarding the Attribution Results of the Second Attribution Tranche of The First Grant and the First Attribution Tranche of the

Reserved Grant and the Listing of Shares under the 2020 Restricted Share Incentive Scheme of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司關於 2020 年限制性股票激勵計劃首次授予部分第二個歸屬期和預留授予部分第一個歸屬期歸屬結果暨股份上市的公告》)(Announcement No.: Lin 2023-010) on the website of Shanghai Stock Exchange (www.sse.com.cn).

II. Details of the nullified restricted shares

Pursuant to relevant requirements of the Management Measures for Share Incentives of Listed Companies* (the “Management Measures”) and the Incentive Scheme, the third attribution tranche for the restricted shares under the first grant shall be from the first trading day following 36 months from the grant date of the restricted shares under the first grant to the last trading day within 48 months from the grant date of the restricted shares under the first grant, which is from 16 November 2023 to 15 November 2024. The second attribution tranche for the restricted shares under the reserved grant shall be from the first trading day following 24 months from the grant date of the restricted shares under the reserved grant to the last trading day within 36 months from the grant date of the restricted shares under the reserved grant, which is from 15 November 2023 to 14 November 2024. As of the date of this announcement, the abovementioned restricted shares that have not been attributed by the end of the attribution tranche shall be invalid and nullified, totaling 8,549,590 shares.

In addition, in the course of the share registration process for the second attribution tranche of the first grant and the first attribution tranche of the reserved grant under the Incentive Scheme, certain participants voluntarily forfeited their rights to an attributed portion of the restricted shares. As a result, 5,760,159 restricted shares granted but yet to be attributed were invalid and nullified (excluding the restricted shares of certain former employees that have been nullified as previously reviewed).

In summary, a total of 14,309,749 restricted shares granted but yet to be attributed have been nullified.

III. Effect of the nullification of restricted shares on the Company

The nullification of certain restricted shares will have no actual impact on the financial condition and operating results of the Company and the stability of its core

team, and the implementation of the Incentive Scheme will be concluded upon completion of the nullification.

IV. Opinions of the board of supervisors

The opinion of the board of supervisors of the Company: the total number of nullified restricted shares is 14,309,749, which is in compliance with relevant requirements of the Management Measures and the Incentive Scheme. The board of supervisors of the Company agreed with the nullification of certain restricted shares.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

30 November 2024